HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer

(2012) Martin Schuler et al.   BREAST CANCER RESEARCH AND TREATMENT

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

(2012) Nancy U. Lin et al.   BREAST CANCER RESEARCH AND TREATMENT

The pan-ErbB tyrosine kinase inhibitor canertinib induces caspase-mediated cell death in human T-cell leukemia (Jurkat) cells

(2011) Cecilia Trinks et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells

(2010) Caroline Brünner-Kubath et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

(2010) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer

(2009) Olivier Rixe et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

3-Phosphoinositide-Dependent Kinase 1 Potentiates Upstream Lesions on the Phosphatidylinositol 3-Kinase Pathway in Breast Carcinoma

(2009) M. Maurer et al.   CANCER RESEARCH

Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions

(2009) Alberto Ocaña et al.   CANCER TREATMENT REVIEWS

Somatic Mutations of ErbB4

(2008) Denis Tvorogov et al.   JOURNAL OF BIOLOGICAL CHEMISTRY